2024 Conference Publication Bivalent peptide agonists targeting peripheral Kappa and Nociceptin heterodimer opioid receptors for the treatment of pain and opioid use disorderHabib, Muhaimin, Saifuddin, Danial, Robitaille, Mélanie and Cabot, Peter (2024). Bivalent peptide agonists targeting peripheral Kappa and Nociceptin heterodimer opioid receptors for the treatment of pain and opioid use disorder. ASCEPT, APFP & APSA Joint Conference, Melbourne, VIC Australia, 1 - 4 December 2024. |
2024 Conference Publication Targeting peripheral mu and delta heterodimer receptors with bivalent opioid peptidesZhang, Junkai, Robitaille, Melanie, Saifuddin, Danial, Ross, Benjamin and Cabot, Peter (2024). Targeting peripheral mu and delta heterodimer receptors with bivalent opioid peptides. ASCEPT, APFP & APSA Joint Conference, Melbourne, VIC Australia, 1 - 4 December 2024. |
2024 Other Outputs Peptides and uses thereofTupally, Karnaker, Cabot, Peter, Nandkumar, Ajit and Parekh, Harendra (2024). Peptides and uses thereof. EP4175970A1. |
2024 Journal Article C-reactive protein (CRP) is associated with chronic pain independently of biopsychosocial factorsFarrell, Scott F., Armfield, Nigel R., Cabot, Peter J., Elphinston, Rachel A., Gray, Paul, Minhas, Gunjeet, Collyer, Martin R. and Sterling, Michele (2024). C-reactive protein (CRP) is associated with chronic pain independently of biopsychosocial factors. The Journal of Pain, 25 (2), 476-496. doi: 10.1016/j.jpain.2023.09.008 |
2023 Conference Publication Leveraging eportfolios to support a learner-centred approach in the Master of Pharmaceutical Industry Practice ProgramCabot, Peter John, Bowker, Shari and Slade, Christine (2023). Leveraging eportfolios to support a learner-centred approach in the Master of Pharmaceutical Industry Practice Program. 2023 Eportfolio Forum: Emerging, Connecting, Sustaining, Darwin, NT, Australia, 11-12 October 2023. Adelaide, SA, Australia: ePortfolios Australia. |
2023 Conference Publication Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potencySaifuddin, D., Lohman, R.-J., Tupally, K., Parekh, H. and Cabot, P. (2023). Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potency. 81st FIP World Congress Of Pharmacy And Pharmaceutical Sciences, Brisbane, QLD Australia, 24-28 September 2023. PKP Publishing. |
2023 Conference Publication Ivermectin effects on interleukin-6 induced nuclear translocation of STAT3 in a macrophage based cell lineCabot, Peter, Daniel, Sona and Alawie, Rayan (2023). Ivermectin effects on interleukin-6 induced nuclear translocation of STAT3 in a macrophage based cell line. 81st FIP World Congress Of Pharmacy And Pharmaceutical Sciences, Brisbane, QLD Australia, 24-28 September 2023. PKP Publishing. doi: 10.46542/pe.2023.236.314328 |
2023 Journal Article Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venomGalante, Priscilla, Campos, Gabriel A. A., Moser, Jacqueline C. G., Martins, Danubia B., Dos Santos Cabrera, Marcia P., Rangel, Marisa, Coelho, Luiza C., Simon, Karina S., Amado, Veronica M., de A. I. Muller, Jessica, Koehbach, Johannes, Lohman, Rink-Jan, Cabot, Peter J., Vetter, Irina, Craik, David J., Toffoli-Kadri, Monica C., Monge-Fuentes, Victoria, Goulart, Jair T., Schwartz, Elisabeth F., Silva, Luciano P., Bocca, Anamelia L. and Mortari, Márcia R (2023). Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom. Scientific Reports, 13 (1) 12491, 1-15. doi: 10.1038/s41598-023-38828-w |
2023 Journal Article Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapyLohman, Rink-Jan, Tupally, Karnaker Reddy, Kandale, Ajit, Cabot, Peter J and Parekh, Harendra S (2023). Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. Frontiers in Pharmacology, 14 1150313, 1150313-14. doi: 10.3389/fphar.2023.1150313 |
2023 Journal Article National wastewater reconnaissance of analgesic consumption in AustraliaAhmed, Fahad, Tscharke, Benjamin, O’Brien, Jake W., Hall, Wayne D., Cabot, Peter J., Sowa, P. Marcin, Samanipour, Saer and Thomas, Kevin V. (2023). National wastewater reconnaissance of analgesic consumption in Australia. Environmental Science and Technology, 57 (4), 1712-1720. doi: 10.1021/acs.est.2c06691 |
2022 Journal Article Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapyLohman, Rink-Jan, Tupally, Karnaker Reddy, Kandale, Ajit, Cabot, Peter J. and Parekh, Harendra S. (2022). Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. British Journal of Pharmacology, 180 (1), 129-129. doi: 10.1111/bph.15862 |
2022 Journal Article Application of mesoporous silica nanoparticles in cancer therapy and delivery of repurposed anthelmintics for cancer therapyKoohi Moftakhari Esfahani, Maedeh, Alavi, Seyed Ebrahim, Cabot, Peter J., Islam, Nazrul and Izake, Emad L. (2022). Application of mesoporous silica nanoparticles in cancer therapy and delivery of repurposed anthelmintics for cancer therapy. Pharmaceutics, 14 (8) 1579, 1-27. doi: 10.3390/pharmaceutics14081579 |
2022 Journal Article β-lactoglobulin-modified mesoporous silica nanoparticles: a promising carrier for the targeted delivery of fenbendazole into prostate cancer cellsEsfahani, Maedeh Koohi Moftakhari, Alavi, Seyed Ebrahim, Cabot, Peter J., Islam, Nazrul and Izake, Emad L. (2022). β-lactoglobulin-modified mesoporous silica nanoparticles: a promising carrier for the targeted delivery of fenbendazole into prostate cancer cells. Pharmaceutics, 14 (4) 884, 884. doi: 10.3390/pharmaceutics14040884 |
2021 Journal Article Pegylated mesoporous silica nanoparticles (MCM-41): a promising carrier for the targeted delivery of fenbendazole into prostrate cancer cellsEsfahani, Maedeh Koohi Moftakhari, Alavi, Seyed Ebrahim, Cabot, Peter J., Islam, Nazrul and Izake, Emad L. (2021). Pegylated mesoporous silica nanoparticles (MCM-41): a promising carrier for the targeted delivery of fenbendazole into prostrate cancer cells. Pharmaceutics, 13 (10) 1605, 1605. doi: 10.3390/pharmaceutics13101605 |
2021 Other Outputs Peptides and uses thereofParekh, Harendra, Tupally, Karnaker, Cabot, Peter and Kandale, Ajit (2021). Peptides and uses thereof. 2021300202. |
2021 Conference Publication Novel opioid peptides as allosteric modulators of nociceptionSaifuddin, Danial, Lohman, Rink-Jan, Tupally, Karnaker Reddy, Parekh, Harendra S. and Cabot, Peter J. (2021). Novel opioid peptides as allosteric modulators of nociception. ASMR medical research week: Queensland virtual symposium, Online, 9-10 June 2021. |
2021 Journal Article Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer TherapyEsfahani, Maedeh Koohi Moftakhari, Islam, Nazrul, Cabot, Peter J. and Izake, Emad L. (2021). Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy. ACS Biomaterials Science and Engineering, 8 (10) acsbiomaterials.1c00066, 4153-4162. doi: 10.1021/acsbiomaterials.1c00066 |
2021 Journal Article Developing GLP-1 conjugated self-assembling nanofibers using copper-catalyzed alkyne–azide cycloaddition and evaluation of their biological activityAlavi, Seyed Ebrahim, Cabot, Peter J., Raza, Aun and Moyle, Peter M. (2021). Developing GLP-1 conjugated self-assembling nanofibers using copper-catalyzed alkyne–azide cycloaddition and evaluation of their biological activity. Bioconjugate Chemistry, 32 (4), 810-820. doi: 10.1021/acs.bioconjchem.1c00091 |
2021 Journal Article Liquid CO2 formulated mesoporous silica nanoparticles for pH-responsive oral delivery of meropenemRaza, Aun, Sime, Fekade Bruck, Cabot, Peter J., Roberts, Jason A., Falconer, James R., Kumeria, Tushar and Popat, Amirali (2021). Liquid CO2 formulated mesoporous silica nanoparticles for pH-responsive oral delivery of meropenem. ACS Biomaterials Science and Engineering, 7 (5) acsbiomaterials.0c01284, 1836-1853. doi: 10.1021/acsbiomaterials.0c01284 |
2020 Journal Article Oral meropenem for superbugs: challenges and opportunitiesRaza, Aun, Ngieng, Shih Chen, Sime, Fekade Bruck, Cabot, Peter J., Roberts, Jason A., Popat, Amirali, Kumeria, Tushar and Falconer, James R. (2020). Oral meropenem for superbugs: challenges and opportunities. Drug Discovery Today, 26 (2), 551-560. doi: 10.1016/j.drudis.2020.11.004 |